Cost-effectiveness analysis: Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169,572 per QALY and exenatide with $278,935 per QALY as second-line treatment in adult diabetics in the USA.
Davis
Wendy A
WA
University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, PO Box 480, Fremantle WA 6959, Australia. wdavis@meddent.uwa.edu.au